The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Key facts
- Where
- Zhuhai, ChinaSee the site
Where in China
- The Fifth Affiliated Hospital Sun Yat-sen UniversityZhuhai, ChinaContact: Xi Liu, MD,PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Trial code
- NCT07920744
- Record updated
- 6 November 2026
- Original description
This retrospective cross-sectional diagnostic study compared the diagnostic performance of ultrasound-measured spleen thickness (ST) and spleen diameter (SD) against esophagogastroduodenoscopy (EGD) for gastroesophageal varices (GOV) and high-risk varices (HRV) detection in patients with compensated cirrhosis.Read full original descriptionShow less
This retrospective cross-sectional diagnostic study compared the diagnostic performance of ultrasound-measured spleen thickness (ST) and spleen diameter (SD) against esophagogastroduodenoscopy (EGD) for gastroesophageal varices (GOV) and high-risk varices (HRV) detection in patients with compensated cirrhosis.
The authors, including senior physicians in infectious diseases and ultrasound, reviewed the medical records and the following data were recorded on a case report form: participants' demographic, etiologic, and laboratory data; SD, ST, portal vein diameter (PVD) and spleen vein diameter (SVD) values; liver stiffness measurement (LSM), spleen stiffness measurement (SSM) by transient elastography (TE); and EGD results.
Inclusion: Age ≥18 years; compensated cirrhosis.
Exclusion: concomitant HIV infection; prior TIPS, endoscopic variceal ligation (EVL), or endoscopic injection sclerotherapy (EIS); receipt of non-selective beta-blockers (NSBBs) or diuretics within 3 months before EGD or abdominal ultrasonography; persistent drug abuse other than alcohol; history of hepatic decompensation, such as ascites, EVB, and hepatic encephalopathy; non-cirrhotic portal hypertension; digestive system malignancies such as hepatocellular carcinoma, pancreatic carcinoma, or other malignant tumors infiltrating the digestive system; history of splenectomy; acute or chronic portal vein thrombosis; acute liver disease, or serum total bilirubin ≥ 100 μmol/L; pregnancy; an interval of more than 6 months between abdominal ultrasonography and EGD, or the absence of results from either examination.